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In the last decades a dramatic increase in human lifespan
has taken place. This is due to relevant ameliorations not
only of living and behavioral conditions, including the
prevention of diseases and vaccinations, but also of dif-
ferent therapeutic approaches to several disease, includ-
ing infections. As a result, HIV-infected elderly persons
are no longer exceptional, but rather a growing popula-
tion experiencing a progressive risk for illnesses and syn-
dromes traditionally associated with aging. The
implications for HIVC patients and their medical pro-
viders are becoming clear: HIV care will intersect rou-
tinely with geriatric medicine.1 This overlap of
traditionally distinct clinical disciplines already occurred
within other medical specialties, including “ortho-geriat-
rics,”2 “cardio-geriatrics,”3 or “onco-geriatrics.”4
In this issue, Virulence invited a series of key experts
in the field of aging in HIV to contribute 8 papers to the
birth of geriatric HIV medicine.
This science is definitely in its infancy. Still, it reflects
the acknowledgment that the emergence and promi-
nence of traditionally age-related illnesses among antire-
troviral therapy (ART)-treated HIV-infected persons at
younger-than-expected ages involves diverse pathophysi-
ological processes characteristic of both HIV infection
and aging.
The debate regarding accentuated or accelerated aging
processes affecting HIV has not yet been resolved.5 From a
clinical perspective, however, the increased prevalence of
frailty and geriatric syndromes6,7 supports the likelihood of
HIV specificity in geriatric syndromes. Many HIV-specific
potential contributing factors have been proposed, including
chronic inflammation, long-term antiretroviral drug toxic-
ity, neurocognitive impairment and higher rates of social
and behavioral risk factors. Last but not least is the change
of body composition observed in HIV patients, in whom
peripheral lipoatrophy characterizing thymidine-analog
treated patients, apparently evolves into a sarcopenic/obesity
phenotype portraying advanced age.8 All this suggests that,
to establish what is “HIV-driven” in the patho-physiology
of aging, the selection of HIV negative control groups is of
paramount importance to discriminate, in each different
geographical setting and for each clinical condition, what
clinical condition is more prevalent (accentuated risk) or
rather occurs at an earlier age (accelerated risk) due to HIV.
Moreover, in the contemporary antiretroviral era, where
HIV viral load un-detectability is a paradigm to all, the point
is not so much to demonstrate that frailty can be reverted by
early start and successful ART. What matters most, once a
patient has reached virological success, is how to reduce the
still perpetuating inflammatory burden to decrease frailty
progression.9
The immune system is clearly of paramount impor-
tance in the aging process, and its changes can ultimately
drive this phenomenon. Indeed, immunosenescence can
be defined as the sum of decreased/altered immune func-
tions in elderly individuals, resulting in age-associated
immune changes that lead to gradual immune dysfunc-
tion. The impaired immune functionality increases sus-
ceptibility to several diseases including infections,
cardiovascular diseases and cancer. Although the main
driving force of immunosenescence is still unclear, evi-
dence suggests that one or several chronic infections such
as that by the cytomegalovirus (CMV) can cause the
exhaustion of the system.10 CMV and other chronic infec-
tions, along with the response required for their control,11
can be at least in part responsible for the so-called inflam-
maging. This is a situation in which the neutralization of
agents that are dangerous or harmful becomes detrimental
during aging.12 Such a situation causes a chronic, low
grade pro-inflammatory status that is associated with or
causes the onset of age-associated diseases.
Most immunological studies agree that an HIV aging
specific phenotype does exist, and accelerated aging is well
evident in patients with HIV infection.13,14 In the papers
published in Virulence, the groups of Appay15 and Tam-
bussi16 discuss the parallels between the progression of
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HIV infection and the aging process. Decades before
uninfected subjects, HIVC patients can experience
changes in innate and adaptive immune responses. In
peripheral blood mononuclear cells from HIVC patients,
telomere length shortens at a very accelerated rate in com-
parison with healthy donors. Lymphocyte populations
change, and cells with a senescent phenotype, particularly
cytotoxic T cells that do not express CD28 but are
CD57C, can accumulate regardless of the presence of
markers related to cell exhaustion, e.g. PD-1. Furthermore,
cells tend to enter a state in which they undergo irrevers-
ible cell cycle arrest in response to intracellular stress or
external stimuli of various kinds, and acquire the so-called
senescence-associated secretory phenotype (SASP). SASP
is characterized by the increased secretion of various
secretory proteins into the surrounding extracellular fluid,
among which pro-inflammatory cytokines, chemokines,
growth factors, and matrix metalloproteinases. Other
aspects of immunological senescence are crucial, and
regard quantitative and qualitative changes in na€ıve T
lymphocytes, memory B cells, expanded NK cells of
inflammatory monocytes and plasmocytoid dendritic cells.
Thus, alterations that define the immunological age
participate in the decline of immune competence with
HIV disease progression. It is therefore important to
characterize these changes, which point toward the accu-
mulation of highly differentiated immunocompetent
cells, associated with overall telomere length shortening,
as well as understanding their etiology, most of all with a
view to the impact of chronic immune activation. Partic-
ular attention should be paid to the exhaustion of pri-
mary immune resources, including haematopoietic
progenitors and na€ıve cells, which holds the key for effec-
tive hematopoiesis and immune response induction,
respectively. The alteration of these compartments dur-
ing HIV infection certainly lays the foundations of the
immune parallel with aging.
Effectively treated HIV infection is associated with
excess risk for multiple non-communicable diseases
(NCDs). These conditions including diabetes, cardiovas-
cular disease, osteoporosis, kidney disease, and chronic
obstructive pulmonary disease, may recognize the
unhealthy life-style prevalent in PLWH or HIV per se as
a risk factor which justifies a disease burden higher than
expected in the general population. NCDs span different
physiologic systems and frequently aggregate in complex
multi-morbidity (MM) pictures.17 These conditions are
all strongly age-related. Therefore, guidelines18 have
developed labor-intensive screening algorithms for the
assessment of clinical and subclinical organ diseases
appropriate to different age strata.
Virulence selected 3 comorbidities to explore clinical
data that support the role of aging as a contributing
factor to metabolic dysregulation, cardiovascular disease
and neurocognitive impairment (NCI).
Aging exhibits an impaired lipid metabolism owing to
hepatic hypo-perfusion, hepatic volume shrinkage and a
decline in overall liver function.19
We therefore argue that, in HIV-infected persons, the
assessment of NAFLD provides a window through which
overall metabolic health can be accurately evaluated. Fur-
thermore, we assert that liver fat content is the modern
“barometer of metabolic health.”20 Martinez suggests
that well-designed studies on dietary interventions and
pharmacological interventions mimicking calorie restric-
tion characterizing the epidemiology, pathogenesis, clini-
cal outcomes and potential therapeutic interventions for
liver disease and associated metabolic dysregulation in
older HIV-infected patients, are urgently needed.21
Cardiovascular disease has become a leading cause of
morbidity and mortality in HIV infected patients. There-
fore, refining risk assessment in a timely fashion is of
paramount importance in this population. Raggi dis-
cusses the contribution of vascular imaging in assessing
coronary age and uncovers valuable prognostic informa-
tion through these tools in this patient category. Vascular
age assessment goes beyond any statistical probability of
risk and allows to identify patient vulnerability in
patients with preclinical cardiovascular disease.22 Finally,
it may be inappropriate to utilize in HIV patients cardio-
vascular risk prediction algorithms (namely Framingham
Risk score and ASCVD) calibrated to predict an “athero-
sclerotic event” in the general population, to estimate the
risk of events which, in more than 50% of the cases, are
non-atherosclerotic in HIVC patients, including sepsis,
vasospasm due to cocaine use, anemia, acute volume
fluctuations etc.23 Future studies may need to address
the calibration of various algorithms to separate the risk
of type-1 from type-2 MI.24
Cognitive impairment and dementia can be included
in geriatric syndromes.25 HIV-infected patients are con-
sidered at increased risk for developing these neurologic
disorders, probably due to a complex chronic inflamma-
tory response to the virus in the CNS.26 Whether prema-
ture brain aging is a real feature of HIV has been
addressed by Krut, using CSF p-tau as a potential marker
for brain aging in HIV. In this large study published in
Virulence, authors found no support for premature CNS
aging in HIV-infected patients as measured by CSF p-
tau concentrations.27
The pathophysiology of age-associated comorbidities
is very complex and includes diagnoses of hypogonad-
ism. In this issue of Virulence, Rochira discusses trajecto-
ries of sex steroid changes overtime in men and their
clinical significance. He suggests that coupling hypogo-
nadal symptoms with documented low serum T
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represents the best strategy to refine the diagnosis of
hypogonadism in older men, and to avoid unnecessary
treatments.28
The transition from co-morbidities to geriatric syn-
drome assessment in HIV implies both a structural and a
cultural change in patient assessment. Greene and co-
authors discuss the assessment of geriatric syndromes
and physical function as useful tools for HIV clinicians
and researchers to help identify the most vulnerable
older adults, and to better understand the aging process
in people living with HIV.29 The geriatric approach goes
beyond a multidisciplinary assessment and involves a
multidimensional process, designed to evaluate an older
person’s functional ability, physical health, cognition and
mental health, and socio-environmental circumstances.
It differs from a standard medical evaluation by includ-
ing nonmedical domains and by emphasizing functional
capacity and quality of life. This so called Comprehen-
sive Geriatric assessments, as explained by Cesari,
includes treatment issues (first of all polypharmacy) that
in “biologically aged” HIV-positive persons might benefit
from models of adapted and integrated care developed
by geriatricians over the years for the management of
their frail and complex patients.30
The next step is to identify clinical and research end
points to be used in HIV-geriatric medicine. The suc-
cessful accomplishment of such cross-disciplinary collab-
oration will not only markedly enhance the care of aging
HIV-infected persons. In fact, it can also constitute a
model of successful healthcare management to be
applied to all aging persons with care needs that increas-
ingly involve geriatric considerations.
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